Literature DB >> 21424799

EGFR/erB-1, HER2/erB-2, CK7, LP34, Ki67 and P53 expression in preneoplastic lesions of bronchial epithelium: an immunohistochemical and genetic study.

Vítor Sousa1, Joana Espírito Santo, Maria Silva, Teresa Cabral, Ana Maria Alarcão, Ana Gomes, Patrícia Couceiro, Lina Carvalho.   

Abstract

A prognostic interpretation of preneoplastic lesions would have impact in bronchial carcinoma early diagnosis and through the study of Erb-B family receptors as they have an important role in lung carcinogenesis. The existence of drugs as tyrosine kinase inhibitors stressed the importance of studying gene alterations for selected chemoprevention schemes and characterization of carcinogenesis. Bronchial preneoplastic lesions were characterized by immunohistochemistry using the antibodies LP34 (high weigh molecular cytokeratin), CK7, chromogranin A, Ki67, p53, C-erbB-2 and EGFR. HER2 and EGFR gene copy number was also evaluated by fluorescent in situ hybridization in those lesions. The expected results defined the origin cell for basal cell hyperplasia and squamous metaplasia as adaptative lesions and dysplasia. By known experiences and published data, beyond the stem cell, the spectral evolution of bronchial preneoplastic lesions was demonstrated by characterizing basal cells (LP34) and their neoplastic potentiality. Dysplasias showed a higher expression of EGFR, Ki67 and p53 with a stepwise increase with the gravity of the respective grading. C-erbB-2 immunohistochemical overexpression was a rare event in preneoplastic lesions. Polysomy was the main mechanism for EGFR and HER2/neu higher gene copy number and together with increased proliferation index (Ki67) will account to preview bronchial carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21424799     DOI: 10.1007/s00428-011-1062-5

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  64 in total

1.  Allele-specific chromosome 3p deletions occur at an early stage in the pathogenesis of lung carcinoma.

Authors:  J Hung; Y Kishimoto; K Sugio; A Virmani; D D McIntire; J D Minna; A F Gazdar
Journal:  JAMA       Date:  1995-06-28       Impact factor: 56.272

Review 2.  How many tumor suppressor genes are involved in human lung carcinogenesis?

Authors:  T Kohno; J Yokota
Journal:  Carcinogenesis       Date:  1999-08       Impact factor: 4.944

3.  Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.

Authors:  Federico Cappuzzo; Fred R Hirsch; Elisa Rossi; Stefania Bartolini; Giovanni L Ceresoli; Lynne Bemis; Jerry Haney; Samir Witta; Kathleen Danenberg; Irene Domenichini; Vienna Ludovini; Elisabetta Magrini; Vanesa Gregorc; Claudio Doglioni; Angelo Sidoni; Maurizio Tonato; Wilbur A Franklin; Lucio Crino; Paul A Bunn; Marileila Varella-Garcia
Journal:  J Natl Cancer Inst       Date:  2005-05-04       Impact factor: 13.506

4.  EGFR, c-erbB-2 and ki-67 in NSCLC and preneoplastic bronchial lesions.

Authors:  A P Meert; B Martin; J M Verdebout; F Feoli; C Mascaux; V Ninane; J P Sculier
Journal:  Anticancer Res       Date:  2006 Jan-Feb       Impact factor: 2.480

5.  Nuclear accumulation of p53 is a potential marker for the development of squamous cell lung cancer in smokers.

Authors:  Chandrika J Piyathilake; Andra R Frost; Upender Manne; Heidi Weiss; Douglas C Heimburger; William E Grizzle
Journal:  Chest       Date:  2003-01       Impact factor: 9.410

6.  Genesis of squamous cell lung carcinoma. Sequential changes of proliferation, DNA ploidy, and p53 expression.

Authors:  T Hirano; B Franzén; H Kato; Y Ebihara; G Auer
Journal:  Am J Pathol       Date:  1994-02       Impact factor: 4.307

7.  Alterations of K-ras, p53, and erbB-2/neu in human lung adenocarcinomas.

Authors:  P F Bongiorno; R I Whyte; E J Lesser; J H Moore; M B Orringer; D G Beer
Journal:  J Thorac Cardiovasc Surg       Date:  1994-02       Impact factor: 5.209

8.  Allele-specific loss in chromosome 9p loci in preneoplastic lesions accompanying non-small-cell lung cancers.

Authors:  Y Kishimoto; K Sugio; J Y Hung; A K Virmani; D D McIntire; J D Minna; A F Gazdar
Journal:  J Natl Cancer Inst       Date:  1995-08-16       Impact factor: 13.506

Review 9.  Tobacco use and its contribution to early cancer mortality with a special emphasis on cigarette smoking.

Authors:  D R Shopland
Journal:  Environ Health Perspect       Date:  1995-11       Impact factor: 9.031

10.  A follow-up study of progression from dysplasia to squamous cell carcinoma with immunohistochemical examination of p53 protein overexpression in the bronchi of ex-chromate workers.

Authors:  Y Satoh; Y Ishikawa; K Nakagawa; T Hirano; E Tsuchiya
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

View more
  3 in total

1.  Identification of relevant prognostic values of cytokeratin 20 and cytokeratin 7 expressions in lung cancer.

Authors:  Hai-Tao Luo; Cai-Xia Liang; Rong-Cheng Luo; Wei-Guang Gu
Journal:  Biosci Rep       Date:  2017-11-06       Impact factor: 3.840

Review 2.  Intratumoral Cellular Heterogeneity: Implications for Drug Resistance in Patients with Non-Small Cell Lung Cancer.

Authors:  Vanesa Gregorc; Chiara Lazzari; Mario Mandalá; Stefania Ippati; Alessandra Bulotta; Maria Giulia Cangi; Abdelrahman Khater; Maria Grazia Viganò; Aurora Mirabile; Lorenza Pecciarini; Francesca Rita Ogliari; Gianluigi Arrigoni; Greta Grassini; Giulia Veronesi; Claudio Doglioni
Journal:  Cancers (Basel)       Date:  2021-04-22       Impact factor: 6.639

3.  Key genes and drug delivery systems to improve the efficiency of chemotherapy.

Authors:  Zally Torres-Martinez; Yamixa Delgado; Yancy Ferrer-Acosta; Ivette J Suarez-Arroyo; Freisa M Joaquín-Ovalle; Louis J Delinois; Kai Griebenow
Journal:  Cancer Drug Resist       Date:  2021-03-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.